WEP Clinical (WEP) announced today that, as of July 2020, it has started a new Named Patient Program (NPP) on behalf of a US biotech company specializing in developing and commercializing novel oncology therapies. [...]
WEP Clinical (WEP) announced today that it has entered into a partnership with BTG Specialty Pharmaceuticals (BTG), a division of Boston Scientific. Under the terms of the partnership, WEP will manage the exclusive distribution [...]
WEP Clinical (WEP), a specialist pharmaceutical services company, has signed an exclusive agreement with Nabriva Therapeutics (Nabriva) to supply XENLETA® (lefamulin) on a named patient or expanded access basis. The Named Patient Program (NPP) [...]
WEP Group Holdings Limited (WEP), a specialist CRO focused on delivering lifesaving drugs to patients that have an unmet clinical need, is expanding its capabilities by making a strategic investment in Wren Healthcare Limited [...]
WEP Clinical (WEP), the specialist pharmaceutical services company, has partnered with Mylan N.V. (Mylan), a global pharmaceutical company, to launch a Named Patient Access Program (NPAP) for a new chemical entity used to treat [...]
WEP Clinical (WEP), the specialist pharmaceutical services company, is committed to helping businesses cope with the current COVID-19 crisis. As part of these efforts, WEP has recently partnered with Wren Healthcare (Wren), a UK-registered [...]
WEP Clinical (“WEP”)’s management team met on 16 March 2020 to discuss the Coronavirus pandemic and agreed to invoke the Group’s Business Continuity plan. WEP believe that fast and decisive leadership is required in [...]
WEP Clinical, the specialist pharmaceutical services company, announces that it has signed an exclusive supply agreement with Wellstat Therapeutics Corporation, the US biopharmaceutical company, to supply Vistogard in the EU and Australia on a [...]